Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Manzoli, Lamberto ^a   de Vito, Corrado ^b   Salanti, Georgia ^c   D'Addario, Maddalena ^b   Villari, Paolo ^b   Ioannidis, John P A ^c,d  

^a UNIVERSITY OF CHIETI   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF IOANNINA   (Greece)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; OIL; WATER;

2009 H1N1 INFLUENZA; ANAPHYLAXIS; ARTICLE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG TOLERABILITY; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOGENICITY; INJECTION SITE PAIN; KNEE ARTHRITIS; LOW DRUG DOSE; MASTOCYTOSIS; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROCONVERSION; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; TREATMENT RESPONSE; ADOLESCENT; ADULT; AGED; CHILD; FEMALE; IMMUNOLOGY; INFANT; INFLUENZA VIRUS A H1N1; MALE; MIDDLE AGED; PRESCHOOL CHILD;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 80052508960     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024384     Document Type: Article

References (71)

1. WHO (2010) Pandemic (H1N1) 2009- update 112. WHO.
2. Manzoli L, Schioppa F, Boccia A, Villari P, (2007) The efficacy of influenza vaccine for healthy children: a meta-analysis evaluating potential sources of variation in efficacy estimates including study quality. Pediatr Infect Dis J 26: 97-106.
3. Villari P, Manzoli L, Boccia A, (2004) Methodological quality of studies and patient age as major sources of variation in efficacy estimates of influenza vaccination in healthy adults: a meta-analysis. Vaccine 22: 3475-3486.
4. Girard MP, Tam JS, Assossou OM, Kieny MP, (2010) The 2009 A (H1N1) influenza virus pandemic: A review. Vaccine 28: 4895-4902.
5. Chan M, (2010) H1N1 in post-pandemic period. WHO.
6. CDC (2011) FluView- 2010-2011 Influenza Season Week 15 ending April 16, 2011.
7. WHO (2010) Recommended viruses for influenza vaccines for use in the 2010-2011 northern hemisphere influenza season: WHO.
8. Arguedas A, Soley C, Lindert K, (2010) Responses to 2009 H1N1 vaccine in children 3 to 17 years of age. N Engl J Med 362: 370-372.
9. Carmona A, Omenaca F, Tejedor JC, Merino JM, Vaman T, et al. (2010) Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Vaccine 28: 5837-5844.
10. Chao DY, Cheng KF, Hsieh YH, Li TC, Wu TN, et al. (2011) Serological response and persistence in schoolchildren with high baseline seropositive rate after receiving 2009 pandemic influenza A(H1N1) vaccine. Vaccine 29: 617-623.
11. Cheong HJ, Song JY, Heo JY, Noh JY, Choi WS, et al. (2011) Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea. Vaccine 29: 523-527.
12. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, et al. (2009) Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 361: 2424-2435.
13. Di B, Xu X, Li T, Lu E, Wu J, et al. (2010) Immunogenicity associated with the routine use of an influenza A H1N1 vaccine in health care personnel in Guangzhou, China. Clin Vaccine Immunol 17: 1478-1480.
14. Esposito S, Tagliaferri L, Daleno C, Valzano A, Picciolli I, et al. (2011) Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. Vaccine 29: 1677-1682.
15. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, et al. (2009) Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 361: 2405-2413.
16. Ikematsu H, Nagai H, Kawashima M, Kawakami Y, Tenjinbaru K, et al. (2010) Immunogenicity and safety of a novel AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan. Hum Vaccin 6: 12-17.
17. Kao TM, Hsieh SM, Kung HC, Lee YC, Huang KC, et al. (2010) Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly. Vaccine 28: 6159-6163.
18. Kung HC, Huang KC, Kao TM, Lee YC, Chang FY, et al. (2010) A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low-level epidemics of pandemic influenza. Vaccine 28: 7337-7343.
19. Liang XF, Wang HQ, Wang JZ, Fang HH, Wu J, et al. (2010) Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 375: 56-66.
20. Loebermann M, Anders G, Brestrich G, Fritzsche C, Klammt S, et al. (2010) Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: A phase III open-label single-arm study. Vaccine 29: 1228-1234.
21. Lu CY, Shao PL, Chang LY, Huang YC, Chiu CH, et al. (2010) Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents. Vaccine 28: 5864-5870.
22. Madhun AS, Akselsen PE, Sjursen H, Pedersen G, Svindland S, et al. (2010) An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine 29: 266-273.
23. Mallory RM, Malkin E, Ambrose CS, Bellamy T, Shi L, et al. (2010) Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials. PLoS One 5: e13755.
24. Mironov AN, Bushmenkov DS, Dyldina NV, Romanova AA, Tsaan AA, et al. (2010) [Study of tolerability and reactogenicity of pandemic vaccines against influenza type A/H1N1]. Zh Mikrobiol Epidemiol Immunobiol pp. 32-35.
25. Nicholson KG, Abrams KR, Batham S, Clark TW, Hoschler K, et al. (2011) Immunogenicity and safety of a two-dose schedule of whole-virion and AS03(A)-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis 11: 91-101.
26. Nolan T, McVernon J, Skeljo M, Richmond P, Wadia U, et al. (2010) Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 303: 37-46.
27. Oh CE, Lee J, Kang JH, Hong YJ, Kim YK, et al. (2010) Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial. Vaccine 28: 5857-5863.
28. Plennevaux E, Blatter M, Cornish MJ, Go K, Kirby D, et al. (2011) Influenza A (H1N1) 2009 two-dose immunization of US children: An observer-blinded, randomized, placebo-controlled trial. Vaccine 29: 1569-1575.
29. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoche MK, Denis M, (2010) Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 375: 41-48.
30. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, et al. (2010) Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 28: 1740-1745.
31. Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P, (2010) AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis 51: 668-677.
32. Sun Y, Bian C, Xu K, Hu W, Wang T, et al. (2010) Immune protection induced on day 10 following administration of the 2009 A/H1N1 pandemic influenza vaccine. PLoS One 5: e14270.
33. Talaat KR, Greenberg ME, Lai MH, Hartel GF, Wichems CH, et al. (2010) A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults. J Infect Dis 202: 1327-1337.
34. Vajo Z, Tamas F, Sinka L, Jankovics I, (2010) Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 375: 49-55.
35. Waddington CS, Walker WT, Oeser C, Reiner A, John T, et al. (2010) Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 340: c2649.
36. Wu J, Li W, Wang HQ, Chen JT, Lv M, et al. (2010) A rapid immune response to 2009 influenza A(H1N1) vaccines in adults: a randomized, double-blind, controlled trial. J Infect Dis 202: 675-680.
37. Yasuda Y, Komatsu R, Matsushita K, Minami T, Suehiro Y, et al. (2010) Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children. Adv Ther 27: 444-457.
38. Zhu FC, Wang H, Fang HH, Yang JG, Lin XJ, et al. (2009) A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 361: 2414-2423.
39. Roman F, Clement F, Dewe W, Walravens K, Maes C, et al. (2011) Effect on cellular and humoral immune responses of the AS03 Adjuvant System in an A/H1N1/2009 influenza vaccine administered to adults during two randomised controlled trials. Clin Vaccine Immunol 18: 835-843.
40. Salanti G, Higgins JP, Ades AE, Ioannidis JP, (2008) Evaluation of networks of randomized trials. Stat Methods Med Res 17: 279-301.
41. Salanti G, Kavvoura FK, Ioannidis JP, (2008) Exploring the geometry of treatment networks. Ann Intern Med 148: 544-553.
42. Juni P, Altman DG, Egger M, (2001) Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 323: 42-46.
43. Manzoli L, Salanti G, De Vito C, Boccia A, Ioannidis JP, et al. (2009) Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis. Lancet Infect Dis 9: 482-492.
44. Coudeville L, Bailleux F, Riche B, Megas F, Andre P, et al. (2010) Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol 10: 18.
45. CPMP CfPMP (1997) Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96). London.
46. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
47. Mantel N, Haenszel W, (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748.
48. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
49. Ioannidis JP, Patsopoulos NA, Evangelou E, (2007) Uncertainty in heterogeneity estimates in meta-analyses. BMJ 335: 914-916.
50. Lu G, Ades AE, (2004) Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 23: 3105-3124.
51. Salanti G, Ades AE, Ioannidis JP, (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64: 163-171.
52. Ioannidis JP, (2009) Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. CMAJ 181: 488-493.
53. Dias S, Welton NJ, Caldwell DM, Ades AE, (2010) Checking consistency in mixed treatment comparison meta-analysis. Stat Med 29: 932-944.
54. Arguedas A, Soley C, Abdelnour A, Sales V, Lindert K, et al. (2011) Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. Hum Vaccin 7: 58-66.
55. Gasparini R, Schioppa F, Lattanzi M, Barone M, Casula D, et al. (2010) Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects. Int J Clin Pract 64: 432-438.
56. GSK GSK Clinical Study Register- study n. 113574.
57. Igari H, Segawa S, Watanabe A, Suzuki A, Watanabe M, et al. (2010) Immunogenicity of a monovalent pandemic influenza A H1N1 vaccine in health-care workers of a university hospital in Japan. Microbiol Immunol 54: 618-624.
58. Scheifele DW, Ward BJ, Dionne M, Vanderkooi O, Langley JM, et al. (2010) Evaluation of Adjuvanted Pandemic H1N12009 Influenza Vaccine After One and Two Doses in Young Children. Pediatr Infect Dis J 30: 402-407.
59. McVernon J, Nolan T, (2011) Panvax((R)): a monovalent inactivated unadjuvanted vaccine against pandemic influenza A (H1N1) 2009. Expert Rev Vaccines 10: 35-43.
60. FDA CfBEaRFaDA- (2007) Guidance for Industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines. Bethesda, MD FDA.
61. Liang XF, Li L, Liu DW, Li KL, Wu WD, et al. (2011) Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China. N Engl J Med 364: 638-647.
62. Vellozzi C, Broder KR, Haber P, Guh A, Nguyen M, et al. (2010) Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010. Vaccine 28: 7248-7255.
63. Yin JK, Khandaker G, Rashid H, Heron L, Ridda I, et al. (2011) Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta-analysis. Influenza Other Respi Viruses.
64. FDA CfBEaRFaDA- (2010) Influenza A (H1N1) 2009 Monovalent. Approved Products.
65. EMA EMA- (2010) Medicines authorised during pandemic.
66. Ioannidis JP, Lau J, (1998) Can quality of clinical trials and meta-analyses be quantified? Lancet 352: 590-591.
67. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I, (2006) The case of the misleading funnel plot. BMJ 333: 597-600.
68. Ioannidis JP, Trikalinos TA, (2007) The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ 176: 1091-1096.
69. Kelly H, Barr I, (2010) Large trials confirm immunogenicity of H1N1 vaccines. Lancet 375: 6-9.
70. Edwards KM, Dupont WD, Westrich MK, Plummer WD Jr, Palmer PS, et al. (1994) A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 169: 68-76.
71. Treanor JJ, Kotloff K, Betts RF, Belshe R, Newman F, et al. (1999) Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 18: 899-906.